Clinical experiment designed to assess clinical efficacy targeting CACNA1G/HCRT/HCRTR1 in human. Primary outcome: Validate Sleep and Respiratory Network Interaction in ALS — Experiment Design
Description
Sleep and Respiratory Network Interaction in ALS — Experiment Design
Background and Rationale
Amyotrophic Lateral Sclerosis (ALS) is characterized by progressive motor neuron degeneration, but emerging evidence suggests that sleep and respiratory dysfunction may represent early pathophysiological changes rather than merely late-stage complications. The brainstem regions controlling sleep-wake cycles and respiratory rhythm generation share anatomical proximity and neurochemical pathways, yet their interaction during ALS progression remains poorly understood. This knowledge gap represents a critical barrier to developing early interventions and biomarkers. This longitudinal clinical study investigates the temporal relationship between sleep architecture disruption and respiratory control network dysfunction across the ALS disease spectrum. We hypothesize that sleep-respiratory network interactions deteriorate early in disease progression and correlate with specific neuroanatomical changes detectable by advanced neuroimaging....
Sleep and Respiratory Network Interaction in ALS — Experiment Design
Background and Rationale
Amyotrophic Lateral Sclerosis (ALS) is characterized by progressive motor neuron degeneration, but emerging evidence suggests that sleep and respiratory dysfunction may represent early pathophysiological changes rather than merely late-stage complications. The brainstem regions controlling sleep-wake cycles and respiratory rhythm generation share anatomical proximity and neurochemical pathways, yet their interaction during ALS progression remains poorly understood. This knowledge gap represents a critical barrier to developing early interventions and biomarkers. This longitudinal clinical study investigates the temporal relationship between sleep architecture disruption and respiratory control network dysfunction across the ALS disease spectrum. We hypothesize that sleep-respiratory network interactions deteriorate early in disease progression and correlate with specific neuroanatomical changes detectable by advanced neuroimaging. The study employs a multi-modal approach combining polysomnography, respiratory function testing, high-resolution MRI, and cerebrospinal fluid biomarker analysis in a carefully stratified ALS cohort. Key innovations include: (1) simultaneous assessment of sleep and respiratory networks rather than isolated evaluation, (2) correlation with brainstem microstructural changes using diffusion tensor imaging, (3) integration of circadian rhythm markers with respiratory muscle electrophysiology, and (4) longitudinal tracking from early to advanced disease stages. Primary measurements encompass sleep efficiency, REM sleep percentage, apnea-hypopnea index, diaphragmatic compound muscle action potentials, forced vital capacity, and brainstem fractional anisotropy values. This comprehensive approach will establish whether sleep-respiratory network dysfunction represents an early disease signature that could guide therapeutic timing and target selection, potentially transforming ALS management from reactive symptom control to proactive network-based intervention.
This experiment directly tests predictions arising from the following hypotheses:
Gamma entrainment therapy to restore hippocampal-cortical synchrony
Sleep Spindle-Synaptic Plasticity Enhancement
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
Phase 1 (Months 1-3): Recruit 120 participants across four groups: early-stage ALS (n=40, ALSFRS-R >35), intermediate ALS (n=40, ALSFRS-R 25-35), advanced ALS (n=20, ALSFRS-R <25), and age-matched controls (n=20). Obtain informed consent and baseline clinical assessments including ALSFRS-R, King's staging, and respiratory symptom questionnaires. Phase 2 (Months 4-18): Conduct comprehensive baseline evaluations every 6 months including overnight polysomnography with respiratory monitoring, pulmonary function testing (FVC, SNIP, MIP), diaphragmatic electromyography, and actigraphy for circadian rhythm assessment. Perform brain and cervical spine MRI with diffusion tensor imaging focusing on brainstem respiratory centers and sleep-wake nuclei. Collect cerebrospinal fluid for neurofilament light chain, phosphorylated tau, and inflammatory markers via lumbar puncture. Phase 3 (Months 19-36): Continue longitudinal follow-up assessments at 6-month intervals with identical protocol. Monitor disease progression using ALSFRS-R decline rates and survival endpoints. Analyze correlations between sleep parameters (sleep efficiency, REM percentage, arousal index) and respiratory metrics (AHI, diaphragmatic CMAP amplitude, FVC decline rate). Phase 4 (Months 37-42): Statistical analysis using mixed-effects models to assess temporal relationships between sleep-respiratory networks and disease progression. Perform DTI tractography analysis of brainstem connectivity changes. Validate predictive models using machine learning approaches incorporating multi-modal biomarkers.
Expected Outcomes
1. Sleep efficiency will decline significantly in early-stage ALS patients (65±12%) compared to controls (78±8%), with p<0.01 and effect size d=1.2, preceding respiratory symptom onset by 8-12 months.
2. REM sleep percentage will show progressive reduction correlating with brainstem DTI changes, decreasing from 18±4% in controls to 12±3% in early ALS and 6±2% in advanced disease (ANOVA p<0.001).
3. Diaphragmatic CMAP amplitude decline will correlate strongly with sleep fragmentation index (r=-0.75, p<0.001), demonstrating shared network vulnerability between sleep and respiratory control systems.
4. Brainstem fractional anisotropy values in the pre-Bötzinger complex region will decrease by 15-25% in early ALS, correlating with both sleep efficiency (r=0.68) and FVC decline rates (r=0.72).
5. Combined sleep-respiratory biomarker panel will predict ALSFRS-R decline rate with 85% accuracy (AUC=0.89) and survival with hazard ratio of 2.3 (95% CI: 1.6-3.2) compared to clinical measures alone.
6. CSF neurofilament light chain levels will correlate with sleep-respiratory dysfunction severity (r=0.71, p<0.001), establishing biochemical validation of network-based pathophysiology.
Success Criteria
• Demonstrate statistically significant sleep architecture changes in early-stage ALS patients with p<0.01 and effect size >0.8 compared to age-matched controls
• Establish temporal precedence of sleep dysfunction over clinical respiratory symptoms by at least 6 months in >70% of longitudinal cases
• Achieve correlation coefficient >0.65 between brainstem DTI metrics and combined sleep-respiratory dysfunction scores
• Develop predictive model with AUC >0.80 for disease progression using integrated sleep-respiratory biomarkers
• Complete longitudinal follow-up in >85% of enrolled participants with <15% dropout rate across 36-month study period
• Validate reproducibility of key findings with inter-rater reliability >0.90 for polysomnography scoring and >0.95 for DTI measurements
TARGET GENE
CACNA1G/HCRT/HCRTR1
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Sleep and Respiratory Network Interaction in ALS — Experiment Design
Phase 1 (Months 1-3): Recruit 120 participants across four groups: early-stage ALS (n=40, ALSFRS-R >35), intermediate ALS (n=40, ALSFRS-R 25-35), advanced ALS (n=20, ALSFRS-R <25), and age-matched controls (n=20). Obtain informed consent and baseline clinical assessments including ALSFRS-R, King's staging, and respiratory symptom questionnaires. Phase 2 (Months 4-18): Conduct comprehensive baseline evaluations every 6 months including overnight polysomnography with respiratory monitoring, pulmonary function testing (FVC, SNIP, MIP), diaphragmatic electromyography, and actigraphy for circadian rhythm assessment. Perform brain and cervical spine MRI with diffusion tensor imaging focusing on brainstem respiratory centers and sleep-wake nuclei.
...
Phase 1 (Months 1-3): Recruit 120 participants across four groups: early-stage ALS (n=40, ALSFRS-R >35), intermediate ALS (n=40, ALSFRS-R 25-35), advanced ALS (n=20, ALSFRS-R <25), and age-matched controls (n=20). Obtain informed consent and baseline clinical assessments including ALSFRS-R, King's staging, and respiratory symptom questionnaires. Phase 2 (Months 4-18): Conduct comprehensive baseline evaluations every 6 months including overnight polysomnography with respiratory monitoring, pulmonary function testing (FVC, SNIP, MIP), diaphragmatic electromyography, and actigraphy for circadian rhythm assessment. Perform brain and cervical spine MRI with diffusion tensor imaging focusing on brainstem respiratory centers and sleep-wake nuclei. Collect cerebrospinal fluid for neurofilament light chain, phosphorylated tau, and inflammatory markers via lumbar puncture. Phase 3 (Months 19-36): Continue longitudinal follow-up assessments at 6-month intervals with identical protocol. Monitor disease progression using ALSFRS-R decline rates and survival endpoints. Analyze correlations between sleep parameters (sleep efficiency, REM percentage, arousal index) and respiratory metrics (AHI, diaphragmatic CMAP amplitude, FVC decline rate). Phase 4 (Months 37-42): Statistical analysis using mixed-effects models to assess temporal relationships between sleep-respiratory networks and disease progression. Perform DTI tractography analysis of brainstem connectivity changes. Validate predictive models using machine learning approaches incorporating multi-modal biomarkers.
Expected Outcomes
1. Sleep efficiency will decline significantly in early-stage ALS patients (65±12%) compared to controls (78±8%), with p<0.01 and effect size d=1.2, preceding respiratory symptom onset by 8-12 months.
2. REM sleep percentage will show progressive reduction correlating with brainstem DTI changes, decreasing from 18±4% in controls to 12±3% in early ALS and 6±2% in advanced disease (ANOVA p<0.001).
3.
...
1. Sleep efficiency will decline significantly in early-stage ALS patients (65±12%) compared to controls (78±8%), with p<0.01 and effect size d=1.2, preceding respiratory symptom onset by 8-12 months.
2. REM sleep percentage will show progressive reduction correlating with brainstem DTI changes, decreasing from 18±4% in controls to 12±3% in early ALS and 6±2% in advanced disease (ANOVA p<0.001).
3. Diaphragmatic CMAP amplitude decline will correlate strongly with sleep fragmentation index (r=-0.75, p<0.001), demonstrating shared network vulnerability between sleep and respiratory control systems.
4. Brainstem fractional anisotropy values in the pre-Bötzinger complex region will decrease by 15-25% in early ALS, correlating with both sleep efficiency (r=0.68) and FVC decline rates (r=0.72).
5. Combined sleep-respiratory biomarker panel will predict ALSFRS-R decline rate with 85% accuracy (AUC=0.89) and survival with hazard ratio of 2.3 (95% CI: 1.6-3.2) compared to clinical measures alone.
6. CSF neurofilament light chain levels will correlate with sleep-respiratory dysfunction severity (r=0.71, p<0.001), establishing biochemical validation of network-based pathophysiology.
Success Criteria
• Demonstrate statistically significant sleep architecture changes in early-stage ALS patients with p<0.01 and effect size >0.8 compared to age-matched controls
• Establish temporal precedence of sleep dysfunction over clinical respiratory symptoms by at least 6 months in >70% of longitudinal cases
• Achieve correlation coefficient >0.65 between brainstem DTI metrics and combined sleep-respiratory dysfunction scores
• Develop predictive model with AUC >0.80 for disease progression using integrated sleep-respiratory biomarkers
• Complete longitudinal follow-up in >85% of enrolled parti
...
• Demonstrate statistically significant sleep architecture changes in early-stage ALS patients with p<0.01 and effect size >0.8 compared to age-matched controls
• Establish temporal precedence of sleep dysfunction over clinical respiratory symptoms by at least 6 months in >70% of longitudinal cases
• Achieve correlation coefficient >0.65 between brainstem DTI metrics and combined sleep-respiratory dysfunction scores
• Develop predictive model with AUC >0.80 for disease progression using integrated sleep-respiratory biomarkers
• Complete longitudinal follow-up in >85% of enrolled participants with <15% dropout rate across 36-month study period
• Validate reproducibility of key findings with inter-rater reliability >0.90 for polysomnography scoring and >0.95 for DTI measurements